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Abstract
Allergic diseases are on the increase, affecting 30-40% of the population. Histamine remains the most important mediator
of clinical reactions in allergic diseases such as rhinitis, urticaria, and food and drug allergies.
The need for more effective and safe antihistamines is critical and intensive drug development has become more
demanding and competitive.
Although the old “first generation” antihistamines were effective, major limitations included their strong potential for
sedation and their anti-cholinergic side effects. Not only could patients not function well in their normal daily activities,
but these medications posed an important risk for safety, particularly for motor vehicle drivers and machine and precision
instrument operators. Unacceptable side effects were a particular problem in the elderly.
In May 2001, CONGA, an international consensus group, convened to formulate guidelines for the development of new
antihistamines. Several important areas were reviewed and a document of recommendations was published, focusing
specifically on the safety and efficacy aspects of antihistamines.1       (SA Fam Pract 2004;47(1): 24-28)
Introduction
The important new issues pertaining
to antihistamines were identified as
follows:
1. Anti-inflammatory properties
2. Potency, efficacy and effectiveness
3. Lack of cardiotoxicity
4. Drug-drug interactions
5. Lack of CNS interactions
In  c lass i fy ing the  ava i lab le
antihistamines, the “first-generation”
antihistamines were those that
historically were the first on the
market (e.g. chlorphenirimine,
diphenhydramine, hydroxyzine). Many
of these are still over-the-counter
medications.
There are four major types of
histamine receptors: H1, H2, H3 and
H4. All are hepta-helical structures that
transduce extracellular signals via G-
proteins and all have constitutive
activity, which is defined as the ability
to trigger downstream events, even in
the absence of ligand binding. The
H1 receptors are the most important
in allergic rhinitis and in chronic
urticaria. They have about 45%
homology with muscarinic receptors,
and this explains why some
antihistamines induce anticholinergic
side effects. Second-generation
antihistamines are less lipophilic than
some of the older, first-generation
antihistamines, and do not cross the
blood brain barrier.
Some of the second-generation
antihistamines, like fexofenadine, are
actively transported into the lumen of
the gut, kidney and brain by p-
glycoproteins, which restrict their
ability to accumulate and cause
unwanted side effects. However,
agents such as rifampicin, which
induce p glycoprotein, may increase
the clearance of fexofenadine and
reduce its efficacy.
The second-generation anti-
histamines were therefore developed
as H1 blockers, which have fewer
unwanted side effects, particularly
sedation. However, two of these,
astemizole and terfenadine, have
serious cardiac side effects, resulting
in prolonged Q-T intervals and
arrhythmias and were withdrawn from
the market. Effective and safe second-
generation antihistamines developed
at this time include cetirizine and
loratadine. Neither of these have
significant cardiac side effects.
It is hoped that the development
of a “third” generation of antihista-
mines, which act differently to current
receptor antagonists and are devoid
of all side effects, will soon be
completed. These are not yet available
commercially.
Recently, new formulations that are
related to previous second-generation
antihistamines have become available
on the South African market. These
include desloratadine, fexofenadine
and levocetirizine, and are currently
referred to as “new-generation”
antihistamines.
The mechanism of histamine
receptor antagonism has recently been
carefully explored in vitro and in vivo,
and it is now understood that the new-
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generation antihistamines, such as
levocetirizine, are actually “inverse
agonists” rather than receptor
antagonists, i.e. they do have intrinsic
activity at the histamine receptor site,
other than competing for histamine 1
binding.
Desirable proper t ies of
antihistamines
The des i rab le  proper t ies  o f
antihistamines were clearly defined
and summarised in the CONGA
consensus document.1
a. Anti-inflammatory properties
It is well understood that chronic
inflammation is an important part of
the pathology of allergic rhinitis and
asthma. There is strong experimental
evidence in vitro that all the new-
generation and second-generation
ant ih is tamines possess ant i -
inflammatory properties related to
inverse agonist effects at the H1
receptor site. These include effects
on eosinophils,2 adhesion molecules,3
T-lymphocytes4 and cytokines. In the
nose, relief of nasal obstruction via
such anti-inflammatory effects would
be of important additional clinical
benefit to blocking the effects of
histamine. The relief of nasal
obstruction by levocetir izine,5
fexofenadine6 and desloratadine
shown in recent studies may be the
result of these anti-inflammatory
activities.
b. Potency, eff icacy and
effectiveness
New antihistamines need to be potent
and specific for the H1 receptor. It has
been found that antihistamines with
the highest affinity for the H1 receptor
may not be the most effective clinically.
It is interesting that, in general, first-
generation antihistamines such as
hydroxyzine and chlorpheniramine are
more effective for the relief of itching
in eczema than the new-generation,
or second-generation, antihistamines.
However, second-generation and new-
generation antihistamines are highly
effective for the relief of itching in
urticaria and rhinitis. The onset of
action is variable, but it is generally
within 90 minutes for the new-
generation antihistamines.
c. Lack of cardiotoxicity
Since the withdrawal of astemizole
and terfenadine from the market, close
survei l lance of  the potent ia l
cardiotoxicity of new antihistamines
has been important. Adverse effects
are consequent to the direct blockade
of potassium channels, which control
the repolarisation phase of the cardiac
action potential.
No clinically significant cardiac
effects have been reported for
loratadine, fexofenadine, des-
loratadine, levocetirizine or cetirizine.
It is advisable, however, to be careful
about using antihistamines in patients
with pre-existent diseases of the
conduction system of the heart, or
patients with ischaemic heart disease
or cardiomyopathy.
d. Lack of CNS effects
Subjective sleepiness is a well-known
side effect of antihistamines. Some
older-generation antihistamines are
even marketed as over-the-counter
sleeping pills. Drowsiness appears to
be a more significant problem in older
subjects and rarely a problem in young
children. Recent studies have shown
that important new-generation
antihistamines, e.g. fexofenadine,7
have no effect on cognition or
psychomotor functions and thus no
impairment of driver behaviour.
Lack of CNS penetration has also
been confirmed for new-generation
antihistamines, such as fexofenadine,
by positron emission tomography
(PET). A lack of CNS side effects is
also important in very young children,
who may be given antihistamines to
prevent the development of asthma.
Excellent tolerability and safety in this
regard has been confirmed by the
ETAC study for cetirizine, which is
used in young children to prevent the
development of asthma.8
e. Lack of drug interactions
Antihistamines that are metabolised
via the P450 cytochromes (CYP) in the
liver have a potential for side effects
when taken in conjunction with
macrolides such as erythromycin, or
with ketoconazole. Antihistamines that
displace active transport mechanisms
(p-glycoprotein) may also influence
drug absorption.
New classes of antihistamines
New classes of antihistamines are
theoretically possible and would act
by binding to histamine and competing
with histamine for the H1 receptors.
Other possible mechanisms would be
by influencing the synthesis or
metabolism of histamine or possibly
by down regulating the expression of
histamine receptors. Such new
compounds are being explored in drug
development programmes. They have
the potential to represent a “third-
generation” antihistamine in the future.
Antihistamines in allergic
rhinitis
Antihistamines remain the mainstay of
the treatment of allergic rhinitis. On
the basis of the international ARIA
guidelines, allergic rhinitis should be
classified as “intermittent” (symptoms
for fewer than four days per week or
fewer than four weeks per year) or
“persistent” (more than four days per
week or more than four weeks).9,10 Mild
allergic rhinitis does not interfere with
normal daily activities, sport, leisure
or sleep.
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Antihistamines are thus recommended
as the first line of treatment for mild or
moderately severe allergic rhinitis.
Intranasal steroids are recommended
for more severe symptoms and when
antihistamines fail to provide adequate
relief of symptoms, e.g. when nasal
obstruction is the dominant symptom.
Anti-histamines are particularly
effective for the relief of symptoms
such as rhinorrhoea, sneezing and
itching. Effective doses for adults are
10 mg cetirizine, 5 mg desloratadine,
5 mg levocetirizine, 10 mg loratadine,
120 mg fexofenadine, and 4 mg
chlorpheniramine. Antihistamines have
also been found to be effective if
applied topically, e.g. levocabastine.
ketotifen eye drops are particularly
effective in relieving the itching and
redness caused by a l le rg ic
conjunctivitis.
Recent studies in South Africa have
found that certain new-generation
antihistamines, e.g. levocetirizine, can
also significantly relieve nasal
obstruction.5
A new and important outcome
measure for antihistamines in rhinitis
is quality of life. The new-generation
antihistamines have a significant
impact on improving quality of life.11
Because of the strong link between
asthma and rhinitis, the beneficial
effect of antihistamines on asthma
symptoms and hospitalisation has
been studied by Peters et al.12
Regular antihistamine or nasal steroid
treatment for rhinitis in patients with
both asthma and rhinit is can
signi f icant ly  reduce hospi ta l
admissions to emergency rooms for
asthma exacerbations.
Antihistamines in urticaria
Antihistamines are highly effective for
and the mainstay of the treatment of
acute and chronic urticaria. They are
recommended for use as the first line
of treatment, and adequate doses of
antihistamines reduce the requirement
for oral steroids in resistant cases of
chronic urticaria.13 Night-time sedation
with hydroxyzine, combined with the
day-time use of a non-sedating
antihistamine such as cetirizine,
fexofenadine, levocetirizine or
desloratadine, is effective and safe for
both adults and children.
In some adult cases, the usual
dose of antihistamine can be doubled
to achieve a better therapeutic effect,
and doses of up to 240mg of
fexofenadine may be helpful in
resistant cases. Children usually
respond well to the recommended
doses.
A few patients will benefit from the
addition of an H2 antihistamine (e.g.
cimetidine). Clearly, antihistamines will
only provide symptom relief, and it is
important in the management of such
patients that a careful history be taken
to identify the triggers and precipitants
of exacerbations, particularly in the
patients’ dietary and medication
history.
Non-sedating antihistamines
effectively relieve the symptoms of
urticaria, as well as the quality of life




safe and are indicated for rhinitis and
urticaria. In atopic dermatitis, the
central sedating effect of the older-
generation antihistamines appears to
be more important and these provide
better symptom control, although side
effects are not uncommon and caution
should be exerted, particularly in the
elderly and patients doing precision
work or driving vehicles.
Antihistamines are now also
considered to be anti-inflammatory
and, although far less potent than
glucocor t icosteroids as ant i -
inflammatory agents, the beneficial
anti-allergic effects related to their
inverse agonist anti-inflammatory
effects are increasingly being
appreciated. 
See CPD Questionnaire, page 30
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